会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Particles for diagnostic and therapeutic use
    • 用于诊断和治疗用途的颗粒
    • US07709273B2
    • 2010-05-04
    • US11273275
    • 2005-11-14
    • Sharat SinghJohn S. PeaseJacqueline SadakianDaniel B. WagnerEdwin F. Ullman
    • Sharat SinghJohn S. PeaseJacqueline SadakianDaniel B. WagnerEdwin F. Ullman
    • G01N33/543G01N31/00
    • G01N33/587C12Q1/6816Y10T436/10C12Q2563/155C12Q2523/319
    • Methods, compositions and kits are disclosed. The compositions are light emitting and comprise a polymeric matrix having dissolved therein a photoactive compound. The composition has the characteristic that, after activation of the photoactive compound, the rate of decrease in the intensity of light emission at any time during a 20-fold decrease in the intensity is proportional to the intensity of the light emission. In one embodiment the polymeric matrix is comprised of particles of about 20 nm to about 100 μm in diameter to which is bound a specific binding pair member. The particles generally comprise a polymeric matrix having dissolved therein about 1 to about 20% by weight of a dopant. The compositions may be used in methods for determining an analyte. A combination is provided comprising (1) a medium suspected of containing the analyte, (2) and the aforementioned composition. The photoactive substance is activated and the effect of the activating on the optical properties of the combination is detected. The presence and amount of the effect is related to the presence and amount of the analyte in the medium. Also disclosed are kits for use in an assay.
    • 公开了方法,组合物和试剂盒。 组合物是发光的并且包含其中溶解有光敏化合物的聚合物基质。 该组合物具有以下特征:在光活性化合物活化后,强度降低20倍的任何时间的发光强度的降低率与发光强度成比例。 在一个实施方案中,聚合物基质包含直径约20nm至约100μm的颗粒,其与特定结合对构件结合。 颗粒通常包含其中溶解约1至约20重量%的掺杂剂的聚合物基质。 该组合物可用于测定分析物的方法中。 提供的组合包括(1)怀疑含有分析物的介质,(2)和上述组合物。 光活性物质被激活,并且检测到激活对组合的光学性质的影响。 影响的存在和数量与介质中分析物的存在和数量有关。 还公开了用于测定的试剂盒。
    • 4. 发明申请
    • Particles for diagnostic and therapeutic use
    • 用于诊断和治疗用途的颗粒
    • US20060121506A1
    • 2006-06-08
    • US11273275
    • 2005-11-14
    • Sharat SinghJohn PeaseJacqueline SadakianDaniel WagnerEdwin Ullman
    • Sharat SinghJohn PeaseJacqueline SadakianDaniel WagnerEdwin Ullman
    • C12Q1/68C07H21/04C12M1/34
    • G01N33/587C12Q1/6816Y10T436/10C12Q2563/155C12Q2523/319
    • Methods, compositions and kits are disclosed. The compositions are light emitting and comprise a polymeric matrix having dissolved therein a photoactive compound. The composition has the characteristic that, after activation of the photoactive compound, the rate of decrease in the intensity of light emission at any time during a 20-fold decrease in the intensity is proportional to the intensity of the light emission. In one embodiment the polymeric matrix is comprised of particles of about 20 nm to about 100 μm in diameter to which is bound a specific binding pair member. The particles generally comprise a polymeric matrix having dissolved therein about 1 to about 20% by weight of a dopant. The compositions may be used in methods for determining an analyte. A combination is provided comprising (1) a medium suspected of containing the analyte, (2) and the aforementioned composition. The photoactive substance is activated and the effect of the activating on the optical properties of the combination is detected. The presence and amount of the effect is related to the presence and amount of the analyte in the medium. Also disclosed are kits for use in an assay.
    • 公开了方法,组合物和试剂盒。 组合物是发光的并且包含其中溶解有光敏化合物的聚合物基质。 该组合物具有以下特征:在光活性化合物活化后,强度降低20倍的任何时间的发光强度的降低率与发光强度成比例。 在一个实施方案中,聚合物基质包括直径约20nm至约100μm的颗粒,其与特定结合对成员结合。 颗粒通常包含其中溶解约1至约20重量%的掺杂剂的聚合物基质。 该组合物可用于测定分析物的方法中。 提供的组合包括(1)怀疑含有分析物的介质,(2)和上述组合物。 光活性物质被激活,并且检测到激活对组合的光学性质的影响。 影响的存在和数量与介质中分析物的存在和数量有关。 还公开了用于测定的试剂盒。